Apellis Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
Apellis Pharmaceuticals, a biopharmaceutical leader in complement therapies, will present at the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022, at 3:00 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Apellis Pharmaceuticals, a biopharmaceutical leader in complement therapies, will present at the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022, at 3:00 p.m. ET. The conference format will be virtual, and interested parties can access the live webcast on the company’s website under the 'Events and Presentations' section. A replay will be available for 90 days post-event. This presentation highlights Apellis's commitment to innovation in treatments for rare and neurological diseases.
Details
News Market Reaction – APLS
The recorded move for APLS in the trading session of this news was +6.11%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will present at the 21st Annual Needham Virtual Healthcare Conference on Monday, April 11, 2022 at 3:00 p.m. ET. The conference will be held in a virtual meeting format.
The event will be available via live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website at https://investors.apellis.com/events-and-presentations. A replay of the webcast will be available for 90 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in complement, we ushered in the first new class of complement medicine in 15 years with the approval of the first and only targeted C3 therapy. We are advancing this science to continually develop transformative medicines for people living with rare, retinal, and neurological diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.